文献速递甲状腺与浅表头颈介入US

单次高强度聚焦超声(HIFU)消融良性甲状腺结节的两年疗效

Two-year efficacy of single-session high-intensity focused ultrasound (HIFU) ablation of benign thyroid nodules.
PubMed 文献 · Eur Radiol · 2018-06-19

108例患者接受单次HIFU治疗良性甲状腺结节,随访24个月。结节体积缩小率在3、6、12、18、24个月分别为51.32±20.71%、62.99±22.05%、68.66±18.48%、69.76±17.88%、70.41±17.39%,梗阻症状VAS从基线4.0(2.0)降至24个月1.0(2.0)。58.3%结节在12至24个月进一步缩小,但20.4%结节体积增加>4.5%。消融前结节体积小是24个月治疗成功的显著决定因素(OR=1.045,95%CI=1.021-1.092,p=0.038)。

要点

  • 单次HIFU后结节体积缩小可持续至24个月,平均缩小率70.41±17.39%。
  • 12至24个月间58.3%结节进一步缩小,但20.4%结节体积增加>4.5%。
  • 消融前结节体积小是24个月治疗成功(VRR≥50%)的显著因素。

核心结论

  • 多数结节在单次HIFU消融后12个月以上仍进一步缩小,但约五分之一结节在12个月后体积明显增加,需要更长的监测期;消融前结节体积小是24个月治疗成功的显著因素。

研究设计与样本

  • 单中心研究(原文未明确写出中心数,仅写108例患者接受单次HIFU治疗),评估结节缩小程度(体积缩小率VRR)和梗阻症状评分(0-10视觉模拟量表VAS)至治疗后24个月,采用二元逻辑回归分析24个月治疗成功(VRR≥50%)的相关因素。

诊断标准与关键数值

  • 治疗成功定义为24个月VRR≥50%;VRR(%)=(基线体积-随访时体积)/基线体积×100;3、6、12、18、24个月平均VRR分别为51.32±20.71%、62.99±22.05%、68.66±18.48%、69.76±17.88%、70.41±17.39%;基线、6、12、24个月中位VAS(IQR)分别为4.0(2.0)、2.0(1.0)、2.0(1.0)、1.0(2.0);消融前结节体积小与24个月治疗成功相关(OR=1.045,95%CI=1.021-1.092,p=0.038)。

临床应用与阅片要点

  • 作者认为,由于约五分之一结节在12个月后体积明显增加,需要更长的监测期;消融前结节体积小是24个月治疗成功的显著因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Assessing the efficacy of single high-intensity focused ultrasound (HIFU) ablation in benign thyroid nodules beyond 12 months.

METHODS: One hundred and eight patients underwent single HIFU treatment. Extent of nodule shrinkage [by volume reduction ratio (VRR)] and obstructive symptom score [by 0-10 visual analogue scale (VAS)] were evaluated for 24 months after treatment. VRR (%) was calculated based on the formula: [baseline volume - volume at visit] / [baseline volume] × 100. Binary logistic regression was performed to evaluate factors associated with 24-month treatment success (VRR ≥ 50%).

RESULTS: After treatment, the mean (± SD) VRR at 3, 6, 12 ,18 and 24 months were 51.32 ± 20.71%, 62.99 ± 22.05%, 68.66 ± 18.48%, 69.76 ± 17.88% and 70.41 ± 17.39%, respectively, while the median (IQR) VAS at baseline, 6, 12 and 24 months was gradually lowered from 4.0 (2.0), 2.0 (1.0), 2.0 (1.0) to 1.0 (2.0), respectively. Sixty-three (58.3%) nodules had a further volume reduction (i.e. > 4.5%) from 12 to 24 months, while 22 (20.4%) nodules had a volume increase of > 4.5% from 12 to 24 months. Small pre-ablation nodule volume was a significant determinant for treatment success at 24 months (OR=1.045, 95% CI=1.021-1.092, p = 0.038).

CONCLUSIONS: A majority of nodules had further volume reduction beyond 12 months after single HIFU ablation, but since one-fifth of nodules had a notable volume increase beyond 12 months, a longer period of surveillance would be necessary. Small pre-ablation nodule volume was a significant factor determining 24-month treatment success.

KEY POINTS: • Small but significant nodule shrinkage continues beyond 12 months after single treatment. • Obstructive symptom continues to improve beyond 12 months after single treatment • Smaller-sized nodules have a greater chance of treatment success at 24 months.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lang BHH, Woo YC, Chiu KW, et al. Two-year efficacy of single-session high-intensity focused ultrasound (HIFU) ablation of benign thyroid nodules. Eur Radiol. 2018. PMID: 29922925. doi:10.1007/s00330-018-5579-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。